Use of valerian lactone A in preparing products containing anti-Staphylococcus aureus

Abstract

The present invention belongs to the field of biomedicine technology, and specifically relates to the use of valerian lactone A in the preparation of products containing anti-Staphylococcus aureus. The valerian lactone A of the present invention has a good inhibitory effect on Staphylococcus aureus, and its source is usually natural biological valerian, the extraction step is simple, and the acquisition cost is low. Furthermore, valerian lactone A is a natural product with little toxic and side effects.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to use of valerian lactone A in preparing products containing anti-Staphylococcus aureus. Background Art

[0002] Staphylococcus aureus is ubiquitous in nature and can be found in air, water, dust, and human and animal excrement. Therefore, there are many opportunities for food to be contaminated by it. According to the US Centers for Disease Control, infections caused by Staphylococcus aureus are the second most common, second only to Escherichia coli. Staphylococcus aureus enterotoxin is a global health problem. In the United States, food poisoning caused by Staphylococcus aureus enterotoxin accounts for 33% of all bacterial food poisoning, and in Canada it is even higher, accounting for 45%. There are also many such poisoning incidents in China every year.

[0003] The epidemiology of Staphylococcus aureus generally has the following characteristics: seasonal distribution, more common in spring and summer; many types of poisoning food, such as milk, meat, eggs, fish and their products. In addition, poisoning incidents caused by leftover rice, fried eggs, glutinous rice cakes and jelly have also been reported. The nasal carriage rate of patients with upper respiratory tract infection is 83%, so the purulent infection sites of humans and animals often become the source of contamination.

[0004] Generally speaking, Staphylococcus aureus can contaminate food through the following ways: food processing personnel, cooks or sales personnel carry the bacteria, causing food contamination; food itself carries the bacteria before processing, or is contaminated during processing, producing enterotoxins and causing food poisoning; cooked food products are not tightly packaged and are contaminated during transportation; when dairy cows suffer from suppurative mastitis or poultry and livestock have local suppuration, they contaminate other parts of the body.

[0005] Staphylococcus aureus is the most common pathogen of human suppurative infections. It can cause local suppurative infections, as well as pneumonia, pseudomembranous enterocolitis, pericarditis, and even systemic infections such as sepsis and septicemia.

[0006] The virulence of Staphylococcus aureus depends mainly on the toxins and invasive enzymes it produces:

[0007] a. Hemolytic toxins: exotoxins, divided into four types: α, β, γ, and δ, can damage platelets, destroy lysosomes, and cause local ischemia and necrosis of the body;

[0008] b. Leukocidin: can destroy human white blood cells and macrophages;

[0009] c. Plasma coagulase: When Staphylococcus aureus invades the human body, this enzyme causes the fibrin in the blood or plasma to deposit on the surface of the bacteria or coagulate, hindering the phagocytic function of phagocytes. The localization of infections caused by Staphylococcus aureus is related to this enzyme;

[0010] d. Deoxyribonuclease: The deoxyribonuclease produced by Staphylococcus aureus can withstand high temperatures and can be used as a basis for identifying Staphylococcus aureus;

[0011] e. Enterotoxin: Staphylococcus aureus can produce several protein enterotoxins that cause acute gastroenteritis, which are divided into five serotypes: A, B, C, D, E and F. Enterotoxins can withstand boiling at 100°C for 30 minutes without being destroyed. The symptoms of food poisoning caused by them are vomiting and diarrhea.

[0012] In addition, Staphylococcus aureus also produces epidermolysin, gelatinase, protease, lipase, peptidase, etc.

[0013] In view of the harm of Staphylococcus aureus, it is necessary to develop products that can inhibit or eliminate Staphylococcus aureus in order to protect or improve the quality of human life. Summary of the invention

[0014] In order to improve the above technical problems, the present invention provides the use of valerian lactone A in the preparation of products containing anti-Staphylococcus aureus, wherein the valerian lactone A has a structure as shown in the following formula I:

[0015]

[0016] According to an embodiment of the present invention, the products containing anti-Staphylococcus aureus are selected from health foods, medical devices, disinfection products and daily chemical products.

[0017] According to an embodiment of the present invention, the medical devices, disinfectants and daily chemicals are selected from products with antibacterial effects such as mouthwash, toothpaste, aromatherapy volatile liquid, dressing, patch, hand sanitizer, hand gel, soap, spray, gynecological lotion, cosmetics, etc.

[0018] According to an embodiment of the present invention, the spray is a disinfecting spray.

[0019] According to an embodiment of the present invention, when valerian lactone A is used to prepare health foods, medical devices, disinfectants and daily chemicals, it acts as a natural preservative or antibacterial agent to significantly reduce the content of Staphylococcus aureus in the above products.

[0020] According to an embodiment of the present invention, the antibacterial rate of valerian lactone A in the product against Staphylococcus aureus is 86% or more, preferably 89% or more, and further preferably 92% or more.

[0021] Beneficial Effects

[0022] The valerian lactone A of the present invention has a good inhibitory effect on Staphylococcus aureus, and its source is usually natural biological valerian, the extraction step is simple, and the acquisition cost is low. Further, valerian lactone A is a natural product with small toxic and side effects. In summary, valerian lactone A has a significant antibacterial effect, is mild and non-irritating in nature, and is not prone to toxic and side effects. It has a wide range of applications, and it is expected that valerian lactone A will be developed into a pure natural plant antibacterial agent, for example, valerian lactone A is used to prepare products with antibacterial effects, such as health foods, medical devices, disinfectants, and daily chemicals. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 It is the 6- and 24-position H-HMBC fragment correlation spectrum of the compound of the present invention.

[0024] Figure 2 It is the 2- and 23-position H-HMBC fragment correlation spectrum of the compound of the present invention.

[0025] Figure 3 is the CH20 of the compound of the present invention 3 -HMBC fragmentation correlation spectrum.

[0026] Figure 4 is the CH at position 11 of the compound of the present invention 3 -HMBC fragmentation correlation spectrum.

[0027] Figure 5 is the 16-CH 3 -HMBC fragmentation correlation spectrum.

[0028] Figure 6 It is the 2, 4, 7 H-HMBC fragment correlation spectrum of the compound of the present invention. DETAILED DESCRIPTION

[0029] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0030] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0031] Example 1 Preparation of valerian lactone A

[0032]

[0033] 1) Extraction: Take 20 kg of valerian root material, grind it and extract it with 50% ethanol (50% ethanol water by weight) by reflux for 2 times, each time for 2 hours, and the amount of ethanol used each time is 120 kg.

[0034] 2) Extraction: Combine the ethanol extracts and concentrate under reduced pressure to a clear paste with a relative density of 1.20, then add n-hexane for extraction and collect the n-hexane extracts.

[0035] 3) Separation: Weigh 700g of 200-300 mesh silica gel, dry-load the column, and use petroleum ether (60-90°C) to elute and balance. Use the above extract as the sample solution to pass through the silica gel chromatography column so that the effective components of the sample solution are completely adsorbed on the silica gel. Then elute with a 99:1 volume ratio of petroleum ether (60-90°C) and ethyl acetate co-solvent, and check the eluted fractions by thin layer chromatography under 254nm ultraviolet light. The developing solvent used in thin layer chromatography is petroleum ether: ethyl acetate (7:1). When the target component appears in the eluted fraction, use a 98:2 volume ratio of petroleum ether (60-90°C) and ethyl acetate co-solvent as the eluent until the target component is no longer detected in the eluted fraction, combine the 98:2 eluted fractions, and concentrate them by rotary evaporator to obtain a crude product;

[0036] The crude product was dissolved in n-hexane and then separated by column chromatography twice according to the above method, and the eluted fraction was concentrated and dried to obtain the pure product. The product was a light yellow oil.

[0037] HPLC detection showed that the purity of the product was 98.8% and the yield was 5.39 g. Since the content of valerian lactone A with a structure as shown in Formula I in the valerian herb was 0.045%, the transfer rate was calculated as follows: 5.39*98.8% / 20000*0.045%=59.2%.

[0038] The detection conditions of the HPLC method are as follows: ODS2 4.6*250mm, 5μm analytical column; column temperature: 30°C; mobile phase: acetonitrile-deionized water (70:30, V / V), flow rate: 0.6ml / min, detection wavelength 268nm, injection volume 20μl.

[0039] The product was detected by UV analysis, and UV(λ MeOH max )=269nm absorption peak, indicating the existence of conjugated system.

[0040] The product was detected by infrared analysis, and the following characteristic absorption peaks appeared in the spectrum: IR (νmax KBr )cm -1:3443.84,2929.24,2871.71,1735.32,1677.59,1622.83,1453.35,1376.10; The above data show that there are functional groups such as methyl, methylene, carbonyl and olefin in the sample structure.

[0041] The product was detected by mass spectrometry, and the results were: EI-MS (me / z): 291.29, 279.25, 263.31, 234.16, 219.04 (100%), 204.98, 190.95, 178.96, 173.06, 148.92, 144.99, 130.92, 119.11, 107.15, 104.92, 90.99, 76.95, 64.99, 54.94;

[0042] MALDI-TOF MS(me / z): 315.1, 299.1, 273.0, 257.0, 235.0.

[0043] In the spectrum, 219.04 (100%).

[0044] The product was tested by NMR, and the results were:

[0045] 1 H-NMR (CDCl 3 , 500MHz) δppm: 9.28 (s, 1H), 6.35 (d, J = 9.5Hz, 1H), 5.35 (dd, J = 5.5Hz, J = 11.5Hz, 1H), 4.18 (d, J = 12.0Hz, 1H), 4.12 (d , J=12.0Hz, 1H), 2.88 (m, 1H), 2.84 (dd, 1H), 2.26 (m, 1H, C14-H), 2.02 (t, 2H, C12-H), 2.00 (s, 3H), 1.28 (s, 3H, C20-CH 3 ), 1.19(s, 3H, C11-CH 3 ), 1.18(s, 3H, C11-CH 3 ), 1.03(s, 3H, C16-CH 3 ), 1.02(s, 3H, C16-CH 3 );

[0046] In the spectrum, at 9.28ppm, an H s peak signal is given, which is the H signal of the aldehyde group at position 24; at 6.35ppm, an H d peak signal with a coupling constant of 9.5Hz is given, which is the H signal of the olefin at position 6; at 5.35ppm, an H dd peak signal with coupling constants of 5.5 and 11.5Hz is given, which is the H signal of the olefin at position 2; at 4.18ppm, an H d peak signal with coupling constants of 12.0Hz is given, which is the H signal at position 23; at 4.12ppm, an H d peak signal with coupling constants of 12.0Hz is given, which is the H signal at position 23; at 2.88ppm, an H, m peak signal is given, which is the H signal at position 13; at 2.84ppm, an H dd peak signal with coupling constants of 12.0Hz is given, which is the H signal at position 4; at 2.02ppm, 3 H, s peak signals are given, which are -OCOCH 3 Group H signal; at 1.28ppm, 3 H,s peak signals are given, which are CH 3 Group H signal; at 1.19ppm, 3 H,s peak signals are given, which are 11-position geminal CH 3 Group H signal; at 1.18ppm, 3 H,s peak signals are given, which are 11-position geminal CH 3 Group H signal; at 1.03ppm, 3 H,s peak signals are given, which are 16-position geminal CH 3 Group H signal; at 1.02ppm, 3 H,s peak signals are given, which are 16-position geminal CH 3 Group H signal;

[0047] 13 C-NMR (CDCl 3 , 125MHz) δppm: 193.80 (d, C-24, aldehyde carbon), 170.89 (s, -OCOCH 3 , acyl carbon), 175.32 (s, C-22, -OC=O), 155.88 (d, C-6, =CH), 142.64 (s, C-5, =C-), 132.94 (s, C-1, =C-), 130.23 (d, C-2, =CH), 85.59 (s, C-20, -OC-), 60.76 (t, C-23, -OCH 2 ), 48.87 (d, C-13, -C-COO), 41.37 (d, C-19, -CH-), 40.65 (t, C-21, -CH 2 -), 40.43(d,C-14,-CH-), 37.01(d,C-8,-CH-), 35.03(d,C-10,-CH-) 2 ), 29.85(q, C20-CH 3), 29.05(s, C11), 28.52(q, C11-CH 3 ), 28.38 (q, C16-CH 3 ), 27.77(t, C-3, -CH 2 ), 26.52(t, C-7, -CH 2 ), 25.31, 24.38(t, C-9, -CH 2 ), 23.94(d,C-17,-CH), 23.75(t,C-18,-CH) 2 ), 23.31(t, C-4, -CH 2 ), 21.07(t, C-15, -CH 2 ), 20.96(q, C-23-OCOCH 3 ), 20.55(t, C-12, -CH 2 ), 15.86(q, C11-CH 3 ), 15.81(q, C16-CH 3 );

[0048] The spectrum shows 31 signals, including 193.80 (d, C-24, aldehyde carbon), 170.89 (s, -OCOCH 3 , acyl carbon), 175.32 (s, C-22, -OC=O) signal is very weak, which is the carbonyl carbon signal; 155.88 (d, C-6, =CH) is a signal containing H protons and 142.64 (s, C-5, =C-) is a quaternary carbon signal, both of which are carbon signals on the olefinic double bond, and there is a conjugated system with the group; 132.94 (s, C-1, =C-) is a quaternary carbon signal and 130.23 (d, C-2, =CH) is a signal containing H protons, both of which are carbon signals on the olefinic double bond; 85.59 (s, C-20, -OC-) is a saturated quaternary carbon signal containing oxygen, 60.76 (t, C-23, -OCH 2 ) is the signal of saturated secondary carbon containing oxygen; 48.87 (d, C-13, -C-COO) is the signal of tertiary carbon containing electron withdrawing group; 41.37 (d, C-19, -CH-), 40.65 (t, C-21, -CH 2 -), 40.43(d,C-14,-CH-), 37.01(d,C-8,-CH-), 35.03(d,C-10,-CH-) 2 ), 29.85(q, C20-CH 3 ) is the primary carbon signal, 29.05 (s, C11), 28.52 (q, C11-CH 3 ) is the primary carbon signal, 28.38 (q, C16-CH 3) is the primary carbon signal, 27.77 (t, C-3, -CH 2 ), 26.52(t, C-7, -CH 2 ), 25.31, 24.38(t, C-9, -CH 2 ), 23.94(d,C-17,-CH), 23.75(t,C-18,-CH) 2 ), 23.31(t, C-4, -CH 2 ), 21.07(t, C-15, -CH 2 ), 20.96(q, C-23-OCOCH 3 ) is the primary carbon signal, 20.55 (t, C-12, -CH 2 ), 15.86(q, C11-CH 3 ) is the primary carbon signal, 15.81 (q, C16-CH 3 ) is the primary carbon signal.

[0049] In the HH cosy spectrum, 6.35 (d, J=9.5 Hz, 1H, C6-H) is correlated with 1.48 (m, 1H), 5.35 (dd, J=5.5 Hz, J=11.5 Hz, 1H, C2-H) is correlated with 2.36, 2.00, 2.88, 2.84 (dd, 1H, C4-H) and 5.35 (dd, J=5.5 Hz, J=11.5 Hz, 1H, C2-H), 2.91 (m, 1H, C13-H) is correlated with 2.26 (m, 1H, C14-H), and 2.02 (t, 2H, C12-H).

[0050] In the HMQC spectrum, 9.28 (s, 1H) and 193.80 (d, C-24, aldehyde carbon), 6.35 (d, J = 9.5 Hz, 1H) and 155.88 (d, C-6, =CH), 5.35 (dd, J = 5.5 Hz, J = 11.5 Hz, 2H) and 130.23 (d, C-2, =CH), 4.18 (d, J = 12.0 Hz, 1H) and 4.12 (d, J = 12.0 Hz, 1H) and 60.76 (t, C-23, -OCH 2 ), 2.91 (m, 1H) and 48.87 (d, C-13, -CH-COO), 2.85 (dd, 1H) and 23.94 (d, C-17, -CH), 2.00 (s, 3H) and 20.96 (q, C-23-OCOCH 3 ), 1.02 (s, 3H) and 15.81 (q, C16-CH 3 ), 1.03 (s, 3H) and 28.38 (q, C16-CH 3), 1.18 (s, 3H) and 15.86 (q, C11-CH 3 ), 1.19 (s, 3H) and 28.52 (q, C11-CH 3 ), 1.28 (s, 3H) and 29.85 (q, C20-CH 3 ) etc. are connected.

[0051] The HMBC spectrum gave 9.28 (s, 1H) and 155.88 (d, C-6, =CH), 142.64 (s, C-5, =C-), 23.31 (t, C-4, -CH 2 ) related; 6.35 (d, J = 9.5 Hz, 1H) and 193.80 (d, C-24, aldehyde carbon), 142.64 (s, C-5, = C-), 23.31 (t, C-4, -CH 2 ) is related, and it can be deduced from the above Figure 1 5.35 (dd, J = 5.5 Hz, J = 11.5 Hz, 1H) and 60.76 (t, C-23, -OCH 2 ), 35.03(t, C-10, -CH 2 -), 27.77(t, C-3, -CH 2 ) related; 4.18 (d, J = 12.0 Hz, 1H) and 4.12 (d, J = 12.0 Hz, 1H) and 170.89 (s, -OCOCH 3 , acyl carbon), 130.23 (d, C-2, =CH), 35.03 (t, C-10, -CH 2 -) related, and the above deduces Figure 2 The fragment shown in . 2.91 (m, 1H) and 26.52 (t, C-12, -CH 2 -) related; 1.28 (s, 3H, C20-CH 3 ) and 41.37(d,C-19,-CH-), 40.65(t,C-21,-CH 2 -), 85.59 (s, C-20, -OC-), and the above results show that Figure 3 The fragment shown in 1.18 (s, 3H, C11-CH 3 ) and 1.19 (s, 3H, C11-CH 3 ) and 37.01(d,C-8,-CH-), 20.55(t,C-12,-CH 2 ), 29.05(s, C11) related, from the above we can deduce Figure 4 The fragment shown in . 1.02 (s, 3H, C16-CH 3 ) and 1.03 (s, 3H, C16-CH3 ) and 21.07 (t, C-15, -CH 2 ), 23.94 (d, C-17, -CH), and the above results indicate Figure 5 The fragment shown in . 27.77 (t, C-3, -CH 2 ) is related to 5.35 (dd, J = 5.5 Hz, J = 11.5 Hz, 1H), 2.84 (dd, 1H, C4-H), 1.48 (m, 1H) is related to 142.64 (s, C-5, =C-), 37.01 (d, C-8, -CH-), and in combination with the HH cosy spectrum, it is deduced Figure 6 The fragment shown in .

[0052] Based on the above analysis, its molecular formula is C 31 H 46 O 5 , confirming that the structure of this compound is as shown in Formula I. This structure is two sesquiterpenes connected together, one of which is a variant sesquiterpene lactone structure, which conforms to the isoprene rule in terms of biogenic pathway.

[0053] Example 2 Inhibitory effect of valerian lactone A on Staphylococcus aureus

[0054] The antibacterial rate test of the example preparation was carried out with reference to Appendix C "Test methods for bactericidal performance, antibacterial performance and stability of products" of "GB15979-2002 Hygiene Standard for Disposable Sanitary Products".

[0055] (1) Antibacterial types

[0056] Staphylococcus aureus (ATCC 6538).

[0057] (2) Preparation of bacterial solution

[0058] Take a fresh slant culture of the nutrient agar medium of the fourth generation of the strain, wash off the bacterial lawn with 5 mL of 0.03 mol / L phosphate buffer (hereinafter referred to as PBS), dilute it with PBS to a bacterial suspension of the test concentration, make the bacterial suspension evenly, and set aside.

[0059] (3) Operation steps

[0060] ① Take 5 mL of the sample solution (the valerian lactone A prepared in Example 1 is weighed and made into a 1% solution with methanol) and 4 tubes of the control solution (5 mL of sterilized distilled water);

[0061] ② Add 100uL of the above bacterial suspension to each sample solution, mix well, and start timing;

[0062] ③ After the bacterial solution and sample solution have reacted for 20 minutes, take 0.5 mL of the sample solution and drop it into a test tube containing 5 mL of PBS, mix thoroughly, make appropriate dilutions, and then take 2 to 3 dilutions;

[0063] ④Pipette 0.5mL of each dilution onto two plates, pour 15mL of nutrient agar medium cooled to 40-45℃, and rotate the plates to make them fully uniform;

[0064] ⑤ After the agar solidifies, turn the plate over and incubate at 35℃±2℃ for 48h before counting the number of live bacterial colonies;

[0065] ⑥ Repeat the test 3 times and calculate the inhibition rate according to the following formula:

[0066] X=(AB) / A×100%

[0067] Where: X is the inhibition rate; A is the colony count of the control sample; B is the colony count of the test sample.

[0068] (4) Test results

[0069]

[0070] The test results show that the antibacterial rate of the sample liquid on Staphylococcus aureus is 92.3%, and the sample has a significant antibacterial effect on Staphylococcus aureus. Therefore, based on the experimental results, valerian lactone A can be applied to health foods, medical devices, disinfectants and daily chemical products to produce mouthwashes, toothpastes, aromatherapy volatile liquids, dressings, patches, hand sanitizers, hand washing gels, soaps, sprays (such as disinfectant sprays), gynecological washes and other products with antibacterial effects, and can also be added to food and cosmetics as a natural preservative or antibacterial agent.

[0071] Example 3: Valerian terpene lactone A is used to prepare antibacterial hand sanitizer

[0072] Wet the hydroxyethyl cellulose with an appropriate amount of anhydrous ethanol, add an appropriate amount of deionized water (70-80° C.) in a magnetic stirrer while stirring, stir for 2 hours, control the temperature at about 70-80° C., and fully swell it into a transparent colloidal solution, which is recorded as liquid A; dissolve the tea saponin powder with an appropriate amount of deionized water, heat and stir until it is completely dissolved, cool it at room temperature, add coconut oil glucoside and stir evenly, which is recorded as liquid B; add liquid B to liquid A, stir it well to mix it, add an appropriate amount of glycerin and stir evenly, add valerian lactone A, add an appropriate amount of sodium bicarbonate to adjust the pH to between 6.5 and 7.0, add an appropriate amount of essence and deionized water, ultrasonicate for 15 minutes to remove foam, and let it stand for 24 hours to obtain the valerian lactone A antibacterial hand sanitizer product.

[0073] Table 1 Ratio of raw materials of antibacterial hand sanitizer (mass ratio)

[0074] raw material effect Ratio(%) Valerian lactone A Antibacterial Agents 1.0 Hydroxyethyl Cellulose Coagulant 0.8 Tea Saponin Powder Surfactants 1.5 Coco-Glucoside Emulsifier 0.2 glycerin Moisturizer 3.0 Sodium bicarbonate pH Adjusters 0.35-0.55 essence Fragrance 0.8 Deionized water Solvents margin

[0075] The antibacterial rate test of the antibacterial hand sanitizer sample obtained in Example 3 was carried out with reference to Appendix C "Test Methods for Product Bactericidal Performance, Antibacterial Performance and Stability" of "GB15979-2002 Hygiene Standards for Disposable Sanitary Products". The results showed that the antibacterial rate of the hand sanitizer sample against Staphylococcus aureus was 91.7%.

[0076] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of valerian lactone A in the preparation of products containing anti-Staphylococcus aureus, wherein the valerian lactone A has a structure as shown in the following formula I:

2. The use according to claim 1, characterized in that The products containing anti-Staphylococcus aureus are selected from health food, medical equipment, disinfection products and daily chemical products.

3. The use according to claim 2, characterized in that: The medical devices, disinfection products and daily chemical products are selected from mouthwashes, toothpastes, aromatherapy volatile liquids, dressings, patches, hand sanitizers, hand washing gels, soaps, sprays, gynecological lotions and cosmetics with antibacterial effects.

4. The use according to claim 3, characterized in that When valerian lactone A is used to prepare health foods, medical devices, disinfectants and daily chemical products, it acts as a natural preservative or antibacterial agent to significantly reduce the content of Staphylococcus aureus in the above products.

5. The use according to claim 3, characterized in that: The spray is a disinfectant spray.

6. The use according to claim 3, characterized in that: The antibacterial rate of the valerian lactone A in the product against Staphylococcus aureus is more than 86%.

7. The use according to claim 6, characterized in that The antibacterial rate of the valerian lactone A in the product against Staphylococcus aureus is more than 89%.

8. The use according to claim 7, characterized in that The antibacterial rate of the valerian lactone A in the product against Staphylococcus aureus is more than 92%.

Images